IP Library Granted Patent US 10,053,445
Granted Patent B2
US 10,053,445 · App. 15/031,628 · Granted Aug 21, 2018

Photocleavable chemical inducers of dimerization (CID) and methods of use

Inventors: Thomas L. Schwarz (Newton, MA); Matthew R. Banghart (Boston, MA); Amos Gutnick (Brookline, MA)
Assignees: Children's Medical Center Corporation; President and Fellows of Harvard College
C07D401/12A61K41/0042C07D239/47C07D239/49C07D401/14C07D405/14C07D473/18C07F15/0053
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,053,445
App. No.
15/031,628
Granted
Aug 21, 2018
Kind
B2
Abstract

The instant invention provides photolysable compounds, and their use in reversible chemical induced dimerization and light-induced regulation of proteins.

Claims (39)

1. A compound represented by the formula R 1 —Y—R 2 , wherein

R 1 is a ligand capable of selectively binding to a first receptor;

R 2 is a ligand capable of selectively binding to a second receptor;

Y is a linker providing a covalent linkage between R 1 and R 2 ,

wherein Y is photocleavable;

R 1 is methotrexate, dexamethasone, 3,5,3′-triiodothyronine, trans-retinoic acid, biotin, coumermycin, tetracycline, lactose, FK506,

analogs or derivatives thereof;

R 2 is

analogs or derivatives thereof,

wherein X═O or NH;

Y is

2. The compound of claim 1 , wherein R 1 is a ligand capable of selectively binding to dihydrofolate reductase (DHFR).

3. The compound of claim 2 , wherein the ligand capable of selectively binding to dihydrofolate reductase is trimethoprim (TMP) or a derivative or analog thereof, or methotrexate or a derivative or analog thereof.

4. The compound of claim 2 , wherein R 2 is a ligand capable of selectively binding to FK506 Binding Protein (FKBP).

5. The compound of claim 4 , wherein the ligand capable of selectively binding to FK506 Binding Protein (FKBP) is a synthetic ligand for FKBP (SLF) or a derivative or analog thereof.

6. The compound of claim 1 , wherein Y is cleavable by exposure to light at a wavelength of about 405 nm.

7. The compound of claim 6 , wherein Y comprises a dimethoxynitrobenzyl (DMNB) moiety or a derivative or analog thereof.

8. A complex comprising a compound of claim 1 complexed to (i) a first protein domain comprising a first binding domain and (ii) a second protein domain comprising a second binding domain.

9. A method of regulating activity of a protein, the method comprising:

(a) providing a complex comprising

(i) a first protein domain comprising a first binding domain;

(ii) a second protein domain comprising a second binding domain; and

(iii) a compound of claim 1 ,

wherein the compound of claim 1 is bound to the first protein domain and the second protein domain;

(b) cleaving the compound of claim 1 by exposure to light, thereby cleaving the complex and regulating activity of the protein.

10. The method of claim 9 , wherein the first binding domain is dihydrofolate reductase (DHFR).

11. The method of claim 10 , wherein the DHFR is E. coli DHFR.

12. The method of claim 9 , wherein the second binding domain is FK506 binding protein (FKBP).

13. The method of claim 9 , wherein the first protein domain comprises one domain of an active protein.

14. The method of claim 9 , wherein the second protein domain comprises another domain of an active protein.

15. The method of claim 9 , wherein the first protein domain and the second protein domain together comprise a functional protein.

16. The method of claim 9 , wherein regulating the activity of a protein comprises inactivating the protein.

17. The method of claim 9 , wherein regulating the activity of a protein comprises activating the protein.

18. A method of regulating the activity of a protein in a cell, the method comprising:

(a) providing a cell that expresses a first protein domain comprising a first binding domain and a second protein domain that comprises a second binding domain;

(b) providing the compound of claim 1 that dimerizes the first and second protein domains; and

(c) cleaving the compound of claim 1 by exposure to light, thereby cleaving the complex and regulating activity of the protein.

19. The method of claim 18 , wherein dimerization of the first and second protein domains produces an active protein.

20. The method of claim 18 , wherein dimerization of the first and second protein domains inactivates the protein.

Assignments (4)
CONFIRMATORY LICENSE Recorded Apr 10, 2020
From: BOSTON CHILDREN'S HOSPITAL
To: NIH-DEITR
Reel/Frame 052368/0041 →
CONFIRMATORY LICENSE Recorded May 30, 2017
From: BOSTON CHILDREN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042611/0054 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2016
From: BANGHART, MATTHEW R.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 038929/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2016
From: SCHWARZ, THOMAS L.; GUTNICK, AMOS
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 038839/0299 →
Continuity (2)
Provisional Application 61895747 · Oct 25, 2013
Related Publication 20160272618A1 · Sep 22, 2016